<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692859</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-201301</org_study_id>
    <nct_id>NCT02692859</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine</brief_title>
  <official_title>A Randomized, Positive-controlled, Non-inferiority Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine in Healthy Infants and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu Olymvax Biopharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Province Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Haemophilus influenza type b (Hib) remains a serious global health threat associated with
      high mortality and morbidity in young children. In China, The overall impact of Hib-related
      infections and the extent of coverage of Hib conjugate vaccines are unclear.Generally,
      vaccination has been considered the most effective way to prevent infection against Hib.In
      order to evaluate safety and immunogenicity of a haemophilus influenzae type b (Hib)
      conjugate vaccine developped by Chengdu Olymvax Biopharmaceuticals Inc. a phase III clinical
      trial is planned to conduct in healthy infants and children in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haemophilus influenza type b (Hib) remains a serious global health threat associated with
      high mortality and morbidity in young children. In China, The overall impact of Hib-related
      infections and the extent of coverage of Hib conjugate vaccines are unclear.Generally,
      vaccination has been considered the most effective way to prevent infection against Hib.In
      order to evaluate safety and immunogenicity of a haemophilus influenzae type b (Hib)
      conjugate vaccine developped by Chengdu Olymvax Biopharmaceuticals Inc. a randomized,
      positive-controlled, non-inferiority phase III clinical trial is planned to conduct in
      healthy infants and children in China.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited Adverse Reactions</measure>
    <time_frame>0-7 days after each dose</time_frame>
    <description>Number of Participants with Solicited Adverse Reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Vaccinees With Anti-polyribosylribitol Phosphate (PRP) Concentrations ≥1.0μg/ml</measure>
    <time_frame>28 days after full course of vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Unsolicited Adverse Reactions</measure>
    <time_frame>0-28 days after each dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Event (SAE) During the Whole Study Period</measure>
    <time_frame>0-84 days for children aged 3-5 months, 0-56 days for children aged 6-11 months and 0-28 days for children aged 1-5 y</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Vaccinees With Anti-polyribosylribitol Phosphate (PRP) Concentrations ≥0.15μg/ml</measure>
    <time_frame>28 days after full course of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Anti-PRP Geometric Mean Concentrations (GMCs)</measure>
    <time_frame>28 days after full course of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Anti-PRP Geometric Mean Fold Increase (GMFI)</measure>
    <time_frame>28 days after full course of vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1992</enrollment>
  <condition>Haemophilus Influenza</condition>
  <arm_group>
    <arm_group_label>Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hib conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine (Walvax Biotechnology Co., LTD.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hib conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib conjugate vaccine</intervention_name>
    <description>Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose</description>
    <arm_group_label>Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)</arm_group_label>
    <arm_group_label>Vaccine (Walvax Biotechnology Co., LTD.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children aged 3-5 months/ 6-11 months/ 1-5 y for each age group

          -  Without vaccination history of Hib conjugate vaccine

          -  One of his/her guardians is able to understand and sign the informed consent

          -  Subjects' guardian can and will comply with the requirements of the protocol

          -  Subjects with temperature &lt;=37.0°C on axillary setting

        Exclusion Criteria:

          -  Subject who has a medical or family history of any of the following: allergic history,
             seizure, epilepsy, brain or mental disease

          -  Subject who is allergic to any ingredient of the vaccines

          -  Subject with damaged or low immune function which has already been known

          -  Subject who had a Hib disease medical history

          -  Subject with acute febrile illness or infectious disease

          -  Major congenital defects, developmental disorders or serious chronic illness

          -  Thrombocytopenia, blood coagulation disorder or bleeding difficulties with
             intramuscular injection

          -  Subject who has serious allergic history

          -  Subject with other medical history not suitable for vaccination such as difficulty for
             blood collection

          -  Any prior administration of immunodepressant or corticosteroids in last 6 months

          -  Any prior administration of blood products in last 3 months

          -  Any prior administration of other research medicine/vaccine in last 30 days

          -  Any prior administration of any attenuated live vaccine in last 14 days

          -  Any prior administration of subunit or inactivated vaccines in last 7 days, such as
             pneumococcal vaccine

          -  Any medical, psychological, social or other condition judged by investigator, that may
             interfere subject's compliance with the protocol or his/her guardian's signature on
             informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <results_first_submitted>September 5, 2016</results_first_submitted>
  <results_first_submitted_qc>July 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2017</results_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)</title>
          <description>Hib conjugate vaccine
Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose</description>
        </group>
        <group group_id="P2">
          <title>Vaccine (Walvax Biotechnology Co., LTD.)</title>
          <description>Hib conjugate vaccine
Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="996"/>
                <participants group_id="P2" count="996"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="912"/>
                <participants group_id="P2" count="901"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)</title>
          <description>Hib conjugate vaccine
Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose</description>
        </group>
        <group group_id="B2">
          <title>Vaccine (Walvax Biotechnology Co., LTD.)</title>
          <description>Hib conjugate vaccine
Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="996"/>
            <count group_id="B2" value="996"/>
            <count group_id="B3" value="1992"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="996"/>
                    <measurement group_id="B2" value="996"/>
                    <measurement group_id="B3" value="1992"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>12-60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.52" spread="12.84"/>
                    <measurement group_id="B2" value="37.32" spread="13.92"/>
                    <measurement group_id="B3" value="37.92" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-11 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.31" spread="1.80"/>
                    <measurement group_id="B2" value="8.20" spread="1.80"/>
                    <measurement group_id="B3" value="8.26" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.26" spread="0.82"/>
                    <measurement group_id="B2" value="4.27" spread="0.83"/>
                    <measurement group_id="B3" value="4.27" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="481"/>
                    <measurement group_id="B2" value="464"/>
                    <measurement group_id="B3" value="945"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="515"/>
                    <measurement group_id="B2" value="532"/>
                    <measurement group_id="B3" value="1047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="996"/>
                    <measurement group_id="B2" value="996"/>
                    <measurement group_id="B3" value="1992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Adverse Reactions</title>
        <description>Number of Participants with Solicited Adverse Reactions</description>
        <time_frame>0-7 days after each dose</time_frame>
        <population>A total of participants in aged 3-5 months,6-11months and 1-5years</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)</title>
            <description>Hib conjugate vaccine
Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose</description>
          </group>
          <group group_id="O2">
            <title>Vaccine (Walvax Biotechnology Co., LTD.)</title>
            <description>Hib conjugate vaccine
Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Adverse Reactions</title>
          <description>Number of Participants with Solicited Adverse Reactions</description>
          <population>A total of participants in aged 3-5 months,6-11months and 1-5years</population>
          <units>Count of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="996"/>
                <count group_id="O2" value="996"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507"/>
                    <measurement group_id="O2" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Vaccinees With Anti-polyribosylribitol Phosphate (PRP) Concentrations ≥1.0μg/ml</title>
        <time_frame>28 days after full course of vaccination</time_frame>
        <posting_date>12/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Unsolicited Adverse Reactions</title>
        <time_frame>0-28 days after each dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Event (SAE) During the Whole Study Period</title>
        <time_frame>0-84 days for children aged 3-5 months, 0-56 days for children aged 6-11 months and 0-28 days for children aged 1-5 y</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Vaccinees With Anti-polyribosylribitol Phosphate (PRP) Concentrations ≥0.15μg/ml</title>
        <time_frame>28 days after full course of vaccination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Anti-PRP Geometric Mean Concentrations (GMCs)</title>
        <time_frame>28 days after full course of vaccination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Anti-PRP Geometric Mean Fold Increase (GMFI)</title>
        <time_frame>28 days after full course of vaccination</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)</title>
          <description>Hib conjugate vaccine
Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose</description>
        </group>
        <group group_id="E2">
          <title>Vaccine (Walvax Biotechnology Co., LTD.)</title>
          <description>Hib conjugate vaccine
Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="996"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="996"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="996"/>
              </event>
              <event>
                <sub_title>viral enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="996"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchopneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="996"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="996"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="996"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="996"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="996"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="996"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kai Chu</name_or_title>
      <organization>jiangsuPCDCP</organization>
      <phone>18915999781</phone>
      <email>chukai19812007@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

